Early Diabetes Interventions May Also Reduce Heart Disease Risk
An estimated 6.5 million Americans in this age group suffer from depression, according to the National Alliance for Mental Illness. To assess the role of depression in cognitive decline among older diabetes patients, Sullivan’s team looked at data on nearly 3,000 people over age 55 with type 2 diabetes and risk factors for cardiovascular events. On average, participants had had diabetes for about 9 years. Tests of cognitive abilities were given to all participants at the study’s beginning, and again at 20 months and 40 months. One test measured psychomotor speed, or how long it takes the brain to register a stimulus, process it and respond. Another looked at the ability to remember words over time. A third test measured executive functioning, or how the brain uses memories to plan actions, pay attention and inhibit inappropriate behavior.
For the original version including any supplementary images or video, visit http://www.reuters.com/article/2013/08/23/us-health-depression-diabetes-dementia-idUSBRE97M0KQ20130823?feedType=RSS&virtualBrandChannel=11563
Study May Explain Why Some Obese People Don’t Get Diabetes
After examining for certain signs of inflammation, the investigators found that those who were not affected by metabolic disorders had lower white blood cell counts and acute-phase response proteins, which are usually elevated in response to inflammation. The study, published in the current issue of the Journal of Clinical Endocrinology & Metabolism, also found those without any metabolic disorders had higher levels of adiponectin, a hormone with anti-inflammatory properties. This was true for both lean and obese people who were metabolically healthy. “From a public health standpoint, we need better methods for identifying which obese people face the greatest risk of diabetes and heart disease,” Phillips concluded.
For the original version including any supplementary images or video, visit http://www.philly.com/philly/health/topics/HealthDay679589_20130827_Study_May_Explain_Why_Some_Obese_People_Don_t_Get_Diabetes.html
These changes could lower the chances of plaque building up in blood vessels. “Cardiovascular disease is the most significant cause of death and disability in people with diabetes,” said the study’s lead author, Ronald Goldberg, MD, of the University of Miami’s Miller School of Medicine. “Our findings demonstrate that the same therapies used to slow the onset of diabetes also may help allay the risk of heart disease.” The randomized clinical trial analyzed blood samples from 1,645 people with impaired glucose tolerance. Participants were randomly assigned to one of three groups — one taking the medication metformin, another taking a placebo and a third undergoing an intensive lifestyle modification program. Researchers compared baseline blood samples from the start of the study to samples taken a year later to measure the interventions’ effects.
For the original version including any supplementary images or video, visit http://www.sciencedaily.com/releases/2013/08/130827134744.htm
Diabetes: Battle for ascendancy escalates in expanding market – KOL Insight
– Appreciate KOL calls for novel therapies and understand the commercial threat and opportunity for current products. – Develop positioning strategies based on KOL insight – Identify critical areas of unmet clinical need and opportunities for better disease management – Evaluate the performance of companies with the most robust new product pipelines – Recognise the key factors KOLs predict will drive future treatment trends Critical questions answered Diabetes: Battle for ascendancy escalates in expanding market answers key questions including: – How might new therapies impact on the current first-line treatments? – What are the current unmet needs and major challenges in diabetes treatment? – What are the most promising late-stage classes in development? – Which therapies are KOLs eagerly awaiting? – How will the new therapies be positioned against each other in each of the disease segments?
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/diabetes-battle-ascendancy-escalates-expanding-211400746.html